Coxon FP - Search Results

1

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Dunford JE, et al. Among authors: coxon fp. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. J Pharmacol Exp Ther. 2001. PMID: 11160603

2

Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.

Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ. Coxon FP, et al. Bone. 2005 Sep;37(3):349-58. doi: 10.1016/j.bone.2005.04.021. Bone. 2005. PMID: 16006204

3

Recent advances in understanding the mechanism of action of bisphosphonates.

Coxon FP, Thompson K, Rogers MJ. Coxon FP, et al. Curr Opin Pharmacol. 2006 Jun;6(3):307-12. doi: 10.1016/j.coph.2006.03.005. Epub 2006 May 2. Curr Opin Pharmacol. 2006. PMID: 16650801 Review.

4

Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.

Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Dunford JE, et al. Among authors: coxon fp. J Bone Miner Res. 2006 May;21(5):684-94. doi: 10.1359/jbmr.060118. J Bone Miner Res. 2006. PMID: 16734383 Free article.

5

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Luckman SP, et al. Among authors: coxon fp. J Bone Miner Res. 1998 Apr;13(4):581-9. doi: 10.1359/jbmr.1998.13.4.581. J Bone Miner Res. 1998. PMID: 9556058 Free article.

6

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Luckman SP, et al. Among authors: coxon fp. J Bone Miner Res. 1998 Nov;13(11):1668-78. doi: 10.1359/jbmr.1998.13.11.1668. J Bone Miner Res. 1998. PMID: 9797474 Free article.

7

Cellular and molecular mechanisms of action of bisphosphonates.

Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Rogers MJ, et al. Among authors: coxon fp. Cancer. 2000 Jun 15;88(12 Suppl):2961-78. doi: 10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.3.co;2-c. Cancer. 2000. PMID: 10898340 Review.

8

Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.

Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Horton MA, Seabra MC, Ebetino FH, Rogers MJ. Coxon FP, et al. J Biol Chem. 2001 Dec 21;276(51):48213-22. doi: 10.1074/jbc.M106473200. Epub 2001 Oct 1. J Biol Chem. 2001. PMID: 11581260 Free article.

9

Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Roelofs AJ, et al. Among authors: coxon fp. Curr Pharm Des. 2010;16(27):2950-60. doi: 10.2174/138161210793563635. Curr Pharm Des. 2010. PMID: 20722616 Review.

10

Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.

Thompson K, Rogers MJ, Coxon FP, Crockett JC. Thompson K, et al. Among authors: coxon fp. Mol Pharmacol. 2006 May;69(5):1624-32. doi: 10.1124/mol.105.020776. Epub 2006 Feb 24. Mol Pharmacol. 2006. PMID: 16501031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters